Company / Net Income
Crinetics Pharmaceuticals, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$465.3M
FY2025
5-year range
-$465.3M / -$107.6M
FY2021-FY2025
Trend
-55.9%
vs FY2024
Sector context
#198 of 216
Health Care
What the data says
Among 216 Health Care companies, Crinetics Pharmaceuticals, Inc. is in the bottom 8% for net income. Net Income has declined for 7 consecutive years, from -$6M in FY2018 to -$465M in FY2025.
Based on SEC 10-K filings.
-$465M in FY2025.
Declined from -$215M to -$465M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 216This company -$465.3M Sector average $454.3M
▼
-202.4% below sector average
Key checks
Key Insights
- Crinetics Pharmaceuticals, Inc.'s net income has declined for 7 consecutive years.
- In FY2025, net income decreased 55.9% year-over-year.
- Ranks #198 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$465.3M | -55.9% |
| FY2024 | -$298.4M | -39.1% |
| FY2023 | -$214.5M | -30.9% |
| FY2022 | -$163.9M | -52.3% |
| FY2021 | -$107.6M | -297.0% |
| FY2020 | -$27.1M | -196.1% |
| FY2019 | -$9.2M | -52.1% |
| FY2018 | -$6.0M | +34.3% |
| FY2017 | -$9.2M | -52.1% |
| FY2016 | -$6.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026